Testing Data
(Figure 1 Overexpression Validation of PD-L1 in 293 CellsLoading: 15 μg of lysates per lane.Antibodies: (A, 0.25 μg/mL; B, 0.5 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution.)
Mouse anti-Human PDL1 Monoclonal Antibody | anti-PDL1 antibody
PDL1 Antibody [6H10]
Supplied in PBS containing 0.02% sodium azide.
IHC starting at 2-5 ug/mL
IF start at 5 ug/mL.
Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested. Knockdown (Knockout, KO validated) Antibody
As with all antibodies care should be taken to avoid repeated freeze thaw cycles.
Antibodies should not be exposed to prolonged high temperatures.
Testing Data
(Figure 1 Overexpression Validation of PD-L1 in 293 CellsLoading: 15 μg of lysates per lane.Antibodies: (A, 0.25 μg/mL; B, 0.5 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution.)
Testing Data
(Figure 1 Overexpression Validation of PD-L1 in 293 CellsLoading: 15 μg of lysates per lane.Antibodies: (A, 0.25 μg/mL; B, 0.5 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution.)
Western Blot (WB)
(Figure 2 Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 μg of lysates per lane.Antibodies: 4059 (2 μg/mL), (2 μg/mL), and beta-actin (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.)
Western Blot (WB)
(Figure 2 Independent Antibody Validation (IAV) via Protein Expression ProfileLoading: 15 μg of lysates per lane.Antibodies: 4059 (2 μg/mL), (2 μg/mL), and beta-actin (1 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit and or anti-mouse IgG HRP conjugate at 1:10000 and 1:5000 dilution, respectively.)
Western Blot (WB)
(Figure 3 Validation with PD-L1 siRNA KnockdownHeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2)Loading: 10 μg of HeLa whole cell lysates per lane.Antibodies: (2 μg/mL) and GAPDH (3783, 0.02 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution.)
Western Blot (WB)
(Figure 3 Validation with PD-L1 siRNA KnockdownHeLa cells were transfected with control siRNAs (lane 1) or PD-L1 siRNAs (lane 2)Loading: 10 μg of HeLa whole cell lysates per lane.Antibodies: (2 μg/mL) and GAPDH (3783, 0.02 μg/mL), 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:5000 dilution.)
Western Blot (WB)
(Figure 4 Western Blot Validation of PD-L1 in Raji CellsLoading: Lysates/proteins at 15 μg per lane.Antibodies: (4 μg/mL). 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:10000 dilution.)
Western Blot (WB)
(Figure 4 Western Blot Validation of PD-L1 in Raji CellsLoading: Lysates/proteins at 15 μg per lane.Antibodies: (4 μg/mL). 1 h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-mouse IgG HRP conjugate at 1:10000 dilution.)
Immunofluorescence (IF)
(Figure 5 Immunofluorescence Validation of PD-L1 in Transfected 293 CellsImmunofluorescent analysis of 4% paraformaldehyde-fixed PD-L1 transfected 293 cells labeling PD-L1 with at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).)
Immunofluorescence (IF)
(Figure 5 Immunofluorescence Validation of PD-L1 in Transfected 293 CellsImmunofluorescent analysis of 4% paraformaldehyde-fixed PD-L1 transfected 293 cells labeling PD-L1 with at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).)
Immunofluorescence (IF)
(Figure 6 Immunofluorescence Validation of PD-L1 in Human Stomach Carcinoma TissueImmunofluorescent analysis of 4% paraformaldehyde-fixed human stomach carcinoma tissue labeling PD-L1 with at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).)
Immunofluorescence (IF)
(Figure 6 Immunofluorescence Validation of PD-L1 in Human Stomach Carcinoma TissueImmunofluorescent analysis of 4% paraformaldehyde-fixed human stomach carcinoma tissue labeling PD-L1 with at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).)
Immunofluorescence (IF)
(Figure 7 Immunofluorescence Validation of PD-L1 in Human Tonsil TissueImmunofluorescent analysis of 4% paraformaldehyde-fixed human tonsil tissue labeling PD-L1 with at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).)
Immunofluorescence (IF)
(Figure 7 Immunofluorescence Validation of PD-L1 in Human Tonsil TissueImmunofluorescent analysis of 4% paraformaldehyde-fixed human tonsil tissue labeling PD-L1 with at 2 μg/mL, followed by goat anti-mouse IgG secondary antibody at 1/500 dilution (red) and DAPI staining (blue).)
Immunohistochemistry (IHC)
(Figure 8 Immunohistochemistry Validation of PD-L1 in Human Stomach Carcinoma TissueImmunohistochemical analysis of paraffin-embedded human stomach carcinoma tissue using anti-PD-L1 antibody at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-mouse IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Lower left: Use mouse IgG antibody at 1 μg/ml as control.)
Immunohistochemistry (IHC)
(Figure 8 Immunohistochemistry Validation of PD-L1 in Human Stomach Carcinoma TissueImmunohistochemical analysis of paraffin-embedded human stomach carcinoma tissue using anti-PD-L1 antibody at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-mouse IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Lower left: Use mouse IgG antibody at 1 μg/ml as control.)
Immunohistochemistry (IHC)
(Figure 9 Immunohistochemistry Validation of PD-L1 in Human Tonsil Carcinoma TissueImmunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-PD-L1 antibody at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-mouse IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Lower left: Use mouse IgG antibody at 1 μg/ml as control.)
Immunohistochemistry (IHC)
(Figure 9 Immunohistochemistry Validation of PD-L1 in Human Tonsil Carcinoma TissueImmunohistochemical analysis of paraffin-embedded human tonsil tissue using anti-PD-L1 antibody at 5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-mouse IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. Lower left: Use mouse IgG antibody at 1 μg/ml as control.)
Immunocytochemistry (ICC)
(Figure 10 Immunocytochemistry Validation of PD-L1Immunocytochemical analysis of 4% paraformaldehyde-fixed PD-L1 transfected 293 cells labeling PD-L1 with at 1 μg/ml, followed by Goat anti-mouse IgG secondary antibody at 1/250 dilution (red). Lower left: Use mouse IgG antibody at 1 μg/ml as control.)
Immunocytochemistry (ICC)
(Figure 10 Immunocytochemistry Validation of PD-L1Immunocytochemical analysis of 4% paraformaldehyde-fixed PD-L1 transfected 293 cells labeling PD-L1 with at 1 μg/ml, followed by Goat anti-mouse IgG secondary antibody at 1/250 dilution (red). Lower left: Use mouse IgG antibody at 1 μg/ml as control.)
NCBI and Uniprot Product Information
Observed: 45 kDa
NCBI Description
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]
Uniprot Description
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077).
Research Articles on PDL1
Similar Products
Product Notes
The PDL1 cd274 (Catalog #AAA154572) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The PDL1 Antibody [6H10] reacts with Human and may cross-react with other species as described in the data sheet. AAA Biotech's PDL1 can be used in a range of immunoassay formats including, but not limited to, ELISA (EIA), Western Blot (WB), Immunohistochemistry (IHC) Paraffin, Immunocytochemistry (ICC), Immunofluorescence (IF). WB at 0.5-1 ug/mL IHC starting at 2-5 ug/mL IF start at 5 ug/mL. Antibody validated: Western Blot in human samples; Immunohistochemistry in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested. Knockdown (Knockout, KO validated) Antibody. Researchers should empirically determine the suitability of the PDL1 cd274 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. It is sometimes possible for the material contained within the vial of "PDL1, Monoclonal Antibody" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.
